. Age diminishes the testicular steroidogenic response to repeated intravenous pulses of recombinant human LH during acute GnRH-receptor blockade in healthy men. Am J Physiol Endocrinol Metab 288: E775-E781, 2005. First published November 30, 2004 doi:10.1152/ajpendo.00410.2004 concentrations fall gradually in healthy aging men. Postulated mechanisms include relative failure of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and/or gonadal Te secretion. Available methods to test Leydig cell Te production include pharmacological stimulation with human chorionic gonadotropin (hCG). We reasoned that physiological lutropic signaling could be mimicked by pulsatile infusion of recombinant human (rh) LH during acute suppression of LH secretion. To this end, we studied eight young (ages 19 -30 yr) and seven older (ages 61-73 yr) men in an experimental paradigm comprising 1) inhibition of overnight LH secretion with a potent selective GnRH-receptor antagonist (ganirelix, 2 mg sc), 2) intravenous infusion of consecutive pulses of rh LH (50 IU every 2 h), and 3) chemiluminometric assay of LH and Te concentrations sampled every 10 min for 26 h. Statistical analyses revealed that 1) ganirelix suppressed LH and Te equally (Ͼ 75% median inhibition) in young and older men, 2) infused LH pulse profiles did not differ by age, and 3) successive intravenous pulses of rh LH increased concentrations of free Te (ng/dl) to 4.6 Ϯ 0.38 (young) and 2.1 Ϯ 0.14 (older; P Ͻ 0.001) and bioavailable Te (ng/dl) to 337 Ϯ 20 (young) and 209 Ϯ 16 (older; P ϭ 0.002). Thus controlled pulsatile rh LH drive that emulates physiological LH pulses unmasks significant impairment of short-term Leydig cell steroidogenesis in aging men. Whether more prolonged pulsatile LH stimulation would normalize this inferred defect is unknown. luteinizing hormone; Leydig cell; aging; male; human HEALTHY MEN EXHIBIT a 30 -50% decline in free and bioavailable testosterone (Te) concentrations in the sixth and later decades of life (10, 22, 24, 29, 38) . Waning Te production in the aging male has been verified by direct sampling of the human spermatic vein, cross-sectional meta-analysis, and longitudinal studies (6 -8, 18). The primary cause is not known. Experimental data in the brown Norway rat indicate that aging reduces testis expression of specific genes encoding cholesterol transport and steroidogenic proteins (17). In this species, in vitro or in vivo exposure of Leydig cells from older animals to luteinizing hormone (LH) does not restore diminished Te secretion over the short term (40) . No comparable insights are available at present in the human.
HEALTHY MEN EXHIBIT a 30 -50% decline in free and bioavailable testosterone (Te) concentrations in the sixth and later decades of life (10, 22, 24, 29, 38) . Waning Te production in the aging male has been verified by direct sampling of the human spermatic vein, cross-sectional meta-analysis, and longitudinal studies (6 -8, 18) . The primary cause is not known. Experimental data in the brown Norway rat indicate that aging reduces testis expression of specific genes encoding cholesterol transport and steroidogenic proteins (17) . In this species, in vitro or in vivo exposure of Leydig cells from older animals to luteinizing hormone (LH) does not restore diminished Te secretion over the short term (40) . No comparable insights are available at present in the human.
Clinical investigations have disclosed several attributes of the aging hypothalamo-pituitary-gonadal axis: 1) minimal or no elevation in LH concentrations concomitantly with low Te availability (2, 32, 37) , 2) variable accentuation of LH release in response to a single intravenous pulse of gonadotropinreleasing hormone (GnRH) (36) , and 3) lower total Te concentrations after intramuscular injection of human chorionic gonadotropin (hCG) (2, 9, 15, 23, 28) . In the last regard, hCG is a pharmacological lutropic stimulus that assesses maximal Te secretion but downregulates Leydig cell responsiveness (5, 25) .
As an alternative strategy to assess the role of gonadal mechanism(s) in mediating reduced Te production in older men, the present study implements a two-step protocol of overnight suppression of LH secretion followed by pulsatile intravenous infusion of recombinant human (rh) LH. According to the null hypothesis, young and older men should achieve comparable rh LH-stimulated Te concentrations if Leydig cell steroidogenesis does not diminish with age.
METHODS
Clinical protocol. The study cohorts comprised eight young men (ages 19 -30 yr, with body mass indexes of 21-26 kg/m 2 ) and seven older men (ages 61-73 yr, with body mass indexes of 22-29 kg/m 2 ). Each subject provided voluntary written informed consent approved by the Institutional Review Board. The study protocol was reviewed by the General Clinical Research Center (GCRC), the National Institutes of Health, and the United States Food and Drug Administration. Entry criteria included an unremarkable medical history, physical examination, and biochemical measures of renal, hepatic, hematologic, and metabolic function and a normal prostate-specific antigen. All subjects had normal fasting serum concentrations of LH, folliclestimulating hormone (FSH), prolactin, Te, estradiol, insulin-like growth factor (IGF-I), thyroxine, and thyroid-stimulating hormone (TSH) (19, 20, 37) . Exclusion criteria included acute or chronic organic disease, alcohol or drug abuse, psychiatric illness, use of any systemic prescription medications, and failure to provide consent. Volunteers were reimbursed for the time spent in participation.
Subjects were admitted to the GCRC in the late afternoon, provided supper at 1800, and given a single subcutaneous injection of the GnRH-receptor antagonist ganirelix (2.0 mg) at 2200. This dose suppresses LH concentrations maximally in young women (1, 27) . On the basis of earlier time-course analyses, Ͼ75% inhibition of LH and Te concentrations emerges after 6 -8 h and persists for 24 -28 h from the time of ganirelix injection (4). To stimulate Te secretion, the first of seven consecutive intravenous injections of rh LH was given at 0800 (10 h after ganirelix administration). The infusion paradigm comprised rh LH (50 IU Serono Laboratory Standard, equivalent to 20 IU First and 15.3 IU Second International Reference Preparation) diluted in sterile water and injected intravenously via commercial pump in 6-min square-wave pulses every 2 h. The last dose was infused at 2000.
Blood was withdrawn in 2 ml samples from a contralateral forearm vein every 10 min for a total of 26 h, beginning at 2000 (2 h before ganirelix administration), until 2200 the next day (2 h after the last rh LH pulse; Fig. 1A) .
Hormone assays. Serum LH and Te concentrations were quantitated in duplicate in each 10-min sample in each subject as a batch using an automated random-access chemiluminescence-based assay (ACS:180; Chiron Diagnostic, Walpole, MA) (34 Analytic methods. Mean, absolute peak (maximum), incremental amplitude (peak minus nadir), peak area, and interpulse nadir concentrations of LH and Te were computed by model-free Cluster analysis (35) . Conservative pulse detection parameters for infused LH peaks included a two-by-two test cluster size and thresholds of t ϭ 2.0 to identify significant upstrokes and downstrokes in the LH time series (31) . The half-lives of distribution and elimination of infused rh LH were quantitated by a new statistically and experimentally validated model of variable-waveform deconvolution analysis (11, 13, 14) .
Statistical methods. Data are presented as means Ϯ SE. Betweenand within-subject contrasts were examined via a two-sample and paired Student's t-test, respectively. Derived measurements were Fig. 1 . A: schema of study protocol. The selective gonadotropin-releasing hormone (GnRH)-receptor antagonist ganirelix (2 mg sc) was administered at 2200 to suppress luteinizing hormone (LH) and testosterone (Te) secretion. Beginning 10 h later at 0800, recombinant human (rh) LH was infused iv every 2 h for 14 h as 7 consecutive 6-min square-wave pulses (50 IU Serono standard ϭ 15.3 IU Second International Reference Preparation). Blood was sampled every 10 min for 2 h before and 24 h after ganirelix administration for later assay of LH and total Te concentrations. B: illustrative LH (left) and total Te (right) concentrations monitored every 10 min for 26 h, beginning 2 h before and continuing 24 h after sc ganirelix injection (solid arrow at 130 min) in one young (top) and one older (bottom) man. Discrete pulses of rh LH were infused iv 2 h apart (beginning at 730 min, open arrow). subjected to logarithmic transformation first. Statistical significance was construed for P Ͻ 0.05.
RESULTS
Baseline free Te (ng/dl) was 1.8 Ϯ 0.21 (young) and 0.67 Ϯ 0.10 (older; P Ͻ 0.01), and bioavailable Te was 204 Ϯ 47 (young) and 136 Ϯ 22 (older; P ϭ 0.043). Figure 1B illustrates paired profiles of LH and total Te concentrations monitored every 10 min for 2 h before and 24 h after injection of ganirelix in one young and one older man. Ganirelix lowered LH and Te concentrations in parallel toward nadir values 6 -8 h thereafter. Thus consecutive intravenous pulses of rh LH were given every 2 h, beginning 10 h after ganirelix injection. Nadir LH and Te concentrations were computed as the 2-h mean just before the first rh LH injection (viz., time interval comprising 8 -10 h after the ganirelix dose; see below).
Statistical analyses revealed that the monoexponential rate (half-life) and absolute extent of decline (decrement) of total Te and LH concentrations did not differ by age (Table 1) . Neither preganirelix baseline nor postganirelix nadir concentrations of LH or total Te differed by age (Fig. 2) . Ganirelix suppressed both hormones by Ͼ75% (median values; P Ͻ 0.01). Mean (14-h) LH concentrations achieved during pulsatile rh LH infusion were also comparable in young and older men ( Table 2 ). Pulse analysis revealed no effect of age on absolute peak (maxima), incremental peak, integrated peak (area), and interpulse nadir (minima) LH concentrations (Table 2).
Total Te concentrations rose rapidly in response to successive pulses of rh LH and reached a plateau after three or four (of 7) pulses (Fig. 1B) . Therefore, values averaged over the last 4 h (2 pulses) of the 14-h rh LH infusion were used to assess stable Te responses. Figure 3 gives individual plateau concentrations of total and bioavailable Te in each of the 15 subjects studied. Total Te concentrations (ng/dl) increased to 629 Ϯ 52 (young) and 506 Ϯ 29 (older; P ϭ 0.14), and bioavailable Te concentrations (ng/dl) rose to 337 Ϯ 20 and 209 Ϯ 16 in young and older subjects, respectively (P Ͻ 0.001). The foregoing differences in total and bioavailable Te measurements were consistent with SHBG concentrations of 41 Ϯ 5.8 (young) and 85 Ϯ 8.2 (older) nmol/l (P Ͻ 0.005). Equilibrium dialysis measurements of free Te concentrations (ng/dl) corroborated a significantly smaller plateau (4-h mean) response to rh LH pulses in older than in young men, viz., 4.6 Ϯ 0.38 (young) and 2.1 Ϯ 0.14 (older; P Ͻ 0.001).
To assess intraindividual incremental Te responses to rh LH, we calculated the algebraic difference between the 2-h mean concentration of Te determined after the last pulse of rh LH (interval, 2000 -2200) and that over the same time interval before ganirelix injection (baseline, 2000 -2200). Concentration increments for total Te (ng/dl) were 243 Ϯ 41 (young) and Data are means Ϯ SE for n as shown. *Decay of endogenous luteinizing hormone (LH) and total testosterone (Te) concentrations over the first 10 h after sc injection of ganirelix. Decrement ϭ [baseline Ϫ nadir], 2-h mean concentration. Comparisons were nonsignificant by age (P Ͼ 0.05). Values are means Ϯ SE for the indicated n. Data are averaged over the 14-h interval of recombinant human LH pulses, i.e., 10 -24 h after ganirelix injection. Peak increment ϭ peak height (maximum) minus prepeak nadir concentration. All age comparisons were P Ͼ 0.05. 124 Ϯ 19 (older; P Ͻ 0.01); for free Te 3.8 Ϯ 0.31 (young) and 1.2 Ϯ 0.17 (older; P Ͻ 0.001); and, as calculated from the raw data shown in Fig. 4 , for bioavailable Te 141 Ϯ 33 (young) and 74 Ϯ 18 (older; P Ͻ 0.005). Thus older volunteers manifested lower plateau and incremental elevations of bioavailable and free Te concentrations than young subjects during rh LH stimulation. Power estimates are that Ͼ80 subjects would need to be studied to detect at Ͼ90% power a Ͼ30% difference in total Te concentrations at P Ͻ 0.05, assuming SHBG concentrations comparable to those reported here (2.1-fold higher in older men).
Hormone concentrations are determined jointly by secretion and elimination rates. Therefore, we applied deconvolution analysis to estimate LH kinetics from the pulsatile concentration profiles. Figure 5 shows that age does not affect the calculated rapid-and slow-phase half-lives of elimination of rh LH. The relative partitioning of the two components (ratio of rapid to total amplitude of elimination) was also comparable at 0.43 (young) and 0.32 (older) (median).
DISCUSSION
The current investigation examines the impact of age in healthy men on testicular Te secretion by implementing an experimental pulsatile LH clamp. The protocol required overnight suppression of LH (and thereby Te) concentrations using a maximally effective dose of a potent selective GnRH receptor antagonist, followed the next morning by stimulation of Leydig cell Te secretion with consecutive intravenous pulses of rh LH. The strategy of administering a GnRH receptor antagonist acutely (overnight) rather than a GnRH receptor agonist chronically (several weeks) was motivated by prominent loss of Leydig cell steroidogenic responsiveness in the human after more prolonged withdrawal of the tropic effects of LH (4, 21) . Fig. 3 . Exogenously stimulated total (left) and bioavailable (right) Te concentrations in 8 young and 7 older men. Data were obtained after administration of a single dose of ganirelix during the last 2 of 7 consecutive iv pulses of rh LH (Fig. 1) . Each value is an individual 4-h mean concentration during the plateau stage of rh LH infusion. P values reflect unpaired parametric comparisons by age. Fig. 4 . Bioavailable Te concentrations measured in healthy young and older men before ganirelix injection (baseline) and after the last of 7 successive iv pulses of rh LH (post-LH). Each datum is the 2-h mean from 1 subject determined at baseline (2000 -2200) and after the last rh LH stimulus (2000 -2200 the next day). SHBG, sex hormone-binding globulin. P values were estimated by paired parametric contrasts.
Under the present stimulation conditions, we demonstrated that healthy older men attain significantly (ϳ50%) lower absolute and incremental free and bioavailable Te concentrations than young men. In contrast, the measured concentrations and calculated kinetics of infused LH did not differ by age. Therefore, we infer that short-term testicular steroidogenic responsiveness to near-physiological LH pulses is significantly attenuated in healthy older men.
The intraindividual increment in, but not the absolute plateau of, total Te concentrations after rh LH stimulation was significantly reduced in aging volunteers. On the other hand, both incremental and absolute responses of free and bioavailable Te concentrations were lower in older individuals. The distinction between the plateau response of total and free or bioavailable Te concentrations is consistent with higher SHBG concentrations in older individuals, as verified here (16, 22, 39) . An implication of the latter difference is that, because the metabolic clearance rate of total Te is inversely related to the SHBG concentration (39), the actual age-related difference in Te secretion is larger than that inferable from total Te concentrations. In contradistinction, the analytically predicted half-life of free Te does not decrease with increased SHBG availability (13) . Thus the observed 54 and 66% reductions in absolute and incremental free Te concentrations, respectively, in older compared with young men should approximately reflect the in vivo age disparity in rh LH-stimulated Te secretion.
Clinical studies have reported normal or minimally elevated LH concentrations and normal or decreased LH bioactivity in healthy, unmedicated, independently living older men (30, 36) . More detailed analyses have indicated that, even in the face of comparable mean LH concentrations, elderly volunteers secrete smaller and more frequent pulses of LH in less regular patterns (12, 19, 20, 26, 37) . Therefore, a key innovation of the current paradigm is assessment of gonadal steroidogenic responses without the potential confounds of aging-related reduced biopotency, attenuated peak amplitude, more frequent LH pulses, and/or more disorderly release patterns. To this end, we utilized a maximally suppressive amount of the GnRH receptor antagonist, which lowered LH (and Te) concentrations by Ͼ75% over 8 -10 h. Earlier dose finding studies allowed validation of a schedule of 6-min bolus intravenous injections of 50 IU rh LH every 2 h to closely approximate the physiological amplitude and frequency of LH pulses in healthy young men (4, 21) . The resultant pulsatile LH clamp offered a means not only to assess testis responsiveness but also to estimate the distribution and elimination kinetics of infused LH in young and elderly men. On the basis of a biexponential decay model, we observed that age does not affect the rapid-or slow-phase half-lives of rh LH or their relative contributions to total elimination. The present kinetic estimates agree with earlier independent data: 1) calculated after bolus intravenous injection of pituitary LH extracts in hypopituitary men and 2) reconstructed analytically from spontaneous LH pulses monitored in normal men (13, 33) .
By way of validity of the current paradigm, a single dose of the GnRH receptor antagonist lowered overnight LH and total Te concentrations equivalently in the two cohorts. In addition, none of the 15 subjects showed downregulation of testis responsiveness to seven successive pulses of rh LH. This outcome differs from that reported after hCG administration (see INTRODUCTION) . Of further relevance to validity, in vitro bioassay of LH has indicated that GnRH receptor antagonists do not directly inhibit Leydig cell Te secretion (3). Our results in the human are congruent with observations in the adult male Norway rat, wherein subcutaneous pulses of ovine LH under systemic Te suppression of LH secretion failed to reinstate in vitro Leydig cell responsiveness in the aged animal (reviewed in Ref. 40 ).
An unresolved mechanistic question is the precise molecular basis for inferentially reduced LH-stimulated Leydig cell steroidogenesis in the older human. Investigations in the aged male rat have revealed decreased Leydig cell LH receptor number, postreceptor signaling, and expression of specific proteins directing sterol uptake, delivery, and utilization in Te biosynthesis (see introductory section). A recent analytical prediction made noninvasively in humans is that aging diminishes the potency and efficacy of feedforward coupling of endogenous LH pulses to Te secretion by 35-50% (13) . No detailed analysis of in vivo LH dose responsiveness is available Fig. 5 . Rapid (distributional) and slow (elimination) half-lives of rh LH infused iv in 6-min square-wave pulses. Disappearance rates were estimated by deconvolution analysis in 8 young and 7 older men after ganirelix-induced suppression of LH secretion (Fig. 1) . Data are means Ϯ SE. P ϭ not significant (NS) denotes P Ͼ 0.05 for an age comparison.
at present in the human or experimental animal to validate this inference directly.
Qualifications in the present study include the relatively short-term (14-h) nature of the stimulation protocol. Whether more prolonged infusion of rh LH pulses would overcome attenuated testicular responsiveness in elderly men remains to be seen. And longitudinal studies will be needed to elucidate the precise age dependency of impaired LH-stimulated Te secretion.
In summary, a paradigm of intermittent intravenous injection of rh LH during GnRH receptor blockade to suppress pituitary LH output unveils attenuation of pulse-stimulated Leydig cell Te secretion in healthy aging men. Reduced testicular responsiveness is evident for both absolute and incremental elevations of free and bioavailable Te concentrations. Further studies will be needed to elucidate the degree of reversibility and the relative age of onset of impaired steroidogenesis in older men.
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